Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Ifrah

Showing results (31-40 of 169) with videos related to

Pageof 17
Sort By:
Oncology|June 13, 2008
Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapyDominique Spaëth, Bernard Desablens, Philippe Rodon, et al.
British Journal of Haematology|September 22, 2009
JAK1 mutations are not frequent events in adult T-ALL: a GRAALL studyVahid Asnafi, Sandrine Le Noir, Ludovic Lhermitte, et al.
Haematologica|December 5, 2015
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trialChristophe Willekens, Odile Blanchet, Aline Renneville, et al.
Thrombosis Research|September 10, 2010
Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosisMarie-Pierre Moles-Moreau, Catherine Ternisien, Aline Tanguy-Schmidt, et al.
Leukemia & Lymphoma|July 12, 2016
Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 studyClara Mariette, Emmanuelle Tavernier, Didier Hocquet, et al.
Blood|May 22, 2009
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemiaJerome Tamburini, Alexa S Green, Valerie Bardet, et al.
Oncotarget|June 13, 2015
Targeting IRAK1 in T-cell acute lymphoblastic leukemiaCharles Dussiau, Amélie Trinquand, Ludovic Lhermitte, et al.
Pharmaceutics|April 23, 2022
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 TrialGuillaume Drevin, Marie Briet, Caroline Bazzoli, et al.
Haematologica|August 30, 2008
Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL studyMathilde Hunault-Berger, Patrice Chevallier, Martine Delain, et al.
European Journal of Haematology|April 18, 2020
R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory studyCarole Lacout, Corentin Orvain, Valérie Seegers, et al.
Pageof 17

Showing results (31-40 of 169) with videos related to

Sort By:
Pageof 17
Oncology|June 13, 2008
Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapyDominique Spaëth, Bernard Desablens, Philippe Rodon, et al.
British Journal of Haematology|September 22, 2009
JAK1 mutations are not frequent events in adult T-ALL: a GRAALL studyVahid Asnafi, Sandrine Le Noir, Ludovic Lhermitte, et al.
Haematologica|December 5, 2015
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trialChristophe Willekens, Odile Blanchet, Aline Renneville, et al.
Thrombosis Research|September 10, 2010
Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosisMarie-Pierre Moles-Moreau, Catherine Ternisien, Aline Tanguy-Schmidt, et al.
Leukemia & Lymphoma|July 12, 2016
Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 studyClara Mariette, Emmanuelle Tavernier, Didier Hocquet, et al.
Blood|May 22, 2009
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemiaJerome Tamburini, Alexa S Green, Valerie Bardet, et al.
Oncotarget|June 13, 2015
Targeting IRAK1 in T-cell acute lymphoblastic leukemiaCharles Dussiau, Amélie Trinquand, Ludovic Lhermitte, et al.
Pharmaceutics|April 23, 2022
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 TrialGuillaume Drevin, Marie Briet, Caroline Bazzoli, et al.
Haematologica|August 30, 2008
Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL studyMathilde Hunault-Berger, Patrice Chevallier, Martine Delain, et al.
European Journal of Haematology|April 18, 2020
R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory studyCarole Lacout, Corentin Orvain, Valérie Seegers, et al.
Pageof 17